| Not Yet Recruiting | ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic M NCT07518940 | Carmen Fava | N/A |
| Not Yet Recruiting | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776 | Stanford University | Phase 1 |
| Not Yet Recruiting | Identification of BCR::ABL1 Mutations by Digital PCR in CML NCT07158294 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Active Not Recruiting | Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination T NCT07022743 | Obafemi Awolowo University | Phase 2 |
| Not Yet Recruiting | Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia NCT06865443 | Assiut University | — |
| Recruiting | Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Net NCT07165535 | University of Milano Bicocca | — |
| Recruiting | Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant NCT06514534 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Tr NCT05589896 | Ossium Health, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRI NCT06646978 | Poitiers University Hospital | — |
| Unknown | Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia NCT04709731 | Associazione Italiana Pazienti Leucemia Mieloide Cronica | Phase 2 |
| Terminated | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-morta NCT03746054 | University Hospital, Angers | Phase 3 |
| Completed | The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans NCT04126707 | Ascentage Pharma Group Inc. | Phase 1 |
| Active Not Recruiting | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors NCT03615105 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors NCT03481868 | University Hospital, Clermont-Ferrand | N/A |
| Unknown | Second STOP After Pioglitazone Priming in CML Patients NCT02889003 | Versailles Hospital | Phase 2 |
| Active Not Recruiting | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haplo NCT02790515 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib NCT02733445 | Bristol-Myers Squibb | — |
| Recruiting | Chronic Myeloid Leukemia (CML) Real-Life Database NCT05963061 | University Hospital, Clermont-Ferrand | — |
| Completed | Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Populat NCT02363868 | Bristol-Myers Squibb | — |
| Withdrawn | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. NCT01605981 | Novartis Pharmaceuticals | Phase 4 |
| Active Not Recruiting | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant NCT02061800 | Diane George | Phase 1 / Phase 2 |
| Completed | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic NCT01667133 | Ariad Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® In NCT01066468 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Natural Killer Cells and Bortezomib to Treat Cancer NCT00720785 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers NCT00488592 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy NCT00433745 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagn NCT00428909 | Novartis Pharmaceuticals | Phase 1 |
| Approved For Marketing | Expanded Access Program of Ponatinib NCT01592136 | Ariad Pharmaceuticals | — |